Abcam and Purely Proteins to Develop Proteome-wide Protein/Antibody Tools for Drug Discovery
Purely Proteins Ltd (Cambridge, UK) and Abcam Ltd (Headquarters, Cambridge, UK) announced a set of collaborative programs leading to the development of protein-antibody pairs that have relevance in pharmaceutical development and span the entire human proteome.
The two companies have formed a collaboration that covers the focused production of families of therapeutically relevant proteins and protein domains together with their corresponding antibodies.
Purely Proteins' TargetBASE database product is being used to provide detailed information about known members of specific therapeutically relevant protein families. TargetBASE's ability to define relationships between the proteins within a family enables their detailed exploration as targets for pharmaceutical and biotherapeutic development. Highly specific antibodies to these therapeutically relevant targets will be designed and produced using Abcam's proprietary processes.
The fruits of this collaboration are being marketed by both companies and will commence with the immediate launch of a number of Protein Tyrosine Phosphatase proteins (PTPs) as off-the-shelf products. The PTPs are validated targets for drug discovery. PTP-1B, a key member of the family, is a proven therapeutic target in diabetes and obesity.
Other protein/antibody combinations that are of specific interest to clients can be accessed immediately via fee-for-service arrangements with the two companies.
Commenting on the collaboration, Abcam's Chief Executive Officer, Dr Jonathan Milner, said, "This collaboration will accelerate our continuing efforts to provide a comprehensive range of antibody-related products for use in drug discovery research and development. We are delighted to be working with Purely Proteins, a company with extensive experience in cloning, protein expression and purification, to provide full-length proteins and active protein domains for use in pharmaceutical development. This, combined with Purely Proteins' use of TargetBASE to define protein relationships, will enable us to add further important products to our expanding portfolio very rapidly."
Dr David Bailey, Chief Executive Officer of Purely Proteins, said, "Abcam is an ideal partner for Purely Proteins in this area. They have considerable expertise in the sourcing, production and sale of antibodies and related products, and have an active program of expansion and development of their antibody range. We are continuing to expand our protein product lines, and access to Abcam's sales and marketing channels will enable Purely Proteins to reach new pharma and biotech clients quickly and efficiently."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
